Pancreatic cancer is a disease with dismal prognosis and treatment options are limited. Development of novel active compounds is mandatory. A number of pancreatic cancer clinical trials that included a novel agent among their arms were presented at the recent 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that IGF-1R inhibition might be effective and this should be tested in further trials. Microtubule stabilization with ixabepilone in combination with EGFR does not lead to promising improvement in prognosis whereas nab-paclitaxel in combination with anti-angiogenetic agents is a combination not previously tested that showed an acceptable safety profile. This combination might be worth testing in a phase II clinical trial. Last but not least, CTLA-4 blockade has an acceptable toxicity profile but its efficacy needs to be proven over placebo in phase II and III trials. Finally, understanding of the tumor biology and biomarker analysis from the clinical trials is warranted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Use of Investigator-Assigned Subjective or Judgmental Efficacy and Toxicity Reporting in Early Phase Clinical Trials of Lung Cancer Treatments.
J Thorac Oncol
December 2024
Division of Medical Oncology, University of Colorado, Aurora, Colorado. Electronic address:
Introduction: Investigator-assigned Subjective or Judgmental Efficacy and Toxicity (ISJET) reporting represents language used to contextualize efficacy or toxicity data in clinical trials that may be inappropriate or misleading. In addition, pooling of grade 1 and 2 adverse events (AEs) may reflect a practice based on acute chemotherapy treatments rather than the expansion of chronic treatments that are now commonplace for many patients with lung cancer. In this study, we set out to evaluate the use of ISJETs and combined grade 1 and 2 reporting in early phase clinical trials of lung treatments at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
View Article and Find Full Text PDF[Highlights of the 2024 ASCO Annual Meeting].
HNO
December 2024
Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Universitätsklinik Ulm, Frauensteige 12, 89075, Ulm, Deutschland.
Survivorship care plans and adherence to breast and cervical cancer screening guidelines among cancer survivors in a national sample.
Support Care Cancer
November 2024
Division of Surgical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Article Synopsis
- The study investigates how components of survivorship care plans, like treatment summaries and follow-up instructions, affect cancer survivors' adherence to breast and cervical cancer screening guidelines.
- It analyzes data from 5,001 breast cancer survivors and 3,014 cervical cancer survivors, revealing that those who received follow-up instructions showed significantly higher adherence to screening recommendations.
- The findings suggest that focusing on improving the distribution of follow-up instructions in survivorship care plans could enhance cancer screening rates among female survivors.
Immune-related and Common Adverse Events With Programmed Cell Death 1/Programmed Cell Death Ligand 1 inhibitors combined with other Anticancer Therapy for Solid Tumors: A Systematic Review and Meta-analysis.
Clin Oncol (R Coll Radiol)
October 2024
Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Sciences, Kitasato University, Shirokane 5-9-1, Minato-ku, Tokyo 108-8641, Japan. Electronic address:
Aims: The combination of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors and anticancer therapies has been in the spotlight in recent years. However, the risks associated with these combination therapies are not fully elucidated. The primary objective of this study was to evaluate the relative risk of organ-specific immune-related adverse events (irAEs) and common adverse events (AEs) in patients treated with PD-1/PD-L1 inhibitor-based combination therapies compared to those treated with PD-1/PD-L1 inhibitor monotherapy for solid tumors.
View Article and Find Full Text PDFAnalysis of 810 tweets from 25 unofficial ASCO representatives (Featured Voices) at ASCO 2024.
J Cancer Policy
December 2024
University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, United States.
Aim Of The Study: The American Society of Clinical Oncology (ASCO) hosts an annual conference and is one of the largest medical conferences globally. For ASCO 2024, they selected 25 Featured Voices, advertising them as individuals to follow on Twitter/X throughout the conference. The aim of this study was to characterize tweets from each of the 25 featured individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!